About Genetix Biotherapeutics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Somerville, Massachusetts
- Company type
- Privately Held
Genetix Biotherapeutics is dedicated to transforming lives through curative therapies.
Formerly bluebird bio, Genetix Biotherapeutics Inc. Is a privately held, commercial-stage biotechnology company dedicated to delivering genetic therapies for patients with severe rare diseases. The company has three FDA-approved genetic therapies for patients living with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. These first-in-class, one-time administered therapies treat the underlying cause of disease and can offer significant and lasting benefits to patients and their families.
Genetix is now better positioned to harness its decades of scientific innovation and extensive clinical data from hundreds of treated patients to more effectively deliver life-changing genetic therapies.
As we enter this new era, Genetix Biotherapeutics is building an ecosystem to expand awareness and access for thousands of untreated patients. Rooted in decades of scientific innovation, we are sharpening our focus on commercial execution, scaling patient access, and enhancing the treatment experience for patients, families, and providers.
Community guidelines:
Specialties
- gene therapy
- gene addition
- sickle cell disease
- beta-thalassemia
- and cerebral adrenoleukodystrophy
Company locations
Somerville, Massachusetts, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
On LinkedIn
- Followers
- 142,185
- People linked to this company
- 145
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.